<DOC>
	<DOCNO>NCT00764881</DOCNO>
	<brief_summary>The aim study investigate whether woman oral contraceptive ( OCs ) suffer acquire OC-associated female sexual dysfunction ( FSD ) least 3 month longer one year express level sexual distress take SH T00658ID compare Microgynon , usual OC prescribe woman OC-associated FSD .</brief_summary>
	<brief_title>Effects SH T00658ID Libido</brief_title>
	<detailed_description />
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>OCassociated female sexual dysfunction ( FSD ) least 3 month longer one year willingness continue OC use switch SH T00658ID Microgynon Combined score sexual desire arousal domains FSFI questionnaire 18 screen baseline Contraindications oral contraceptive use , example limit : presence history venous arterial thrombotic / thromboembolic event , hypertension , presence history severe hepatic disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Oral contraceptive</keyword>
	<keyword>Sexual dysfunction</keyword>
	<keyword>Libido</keyword>
</DOC>